The overall objective of the proposed studies is to develop an improved method for delivering interferon to diseased brain tissue. A mouse glioma has been chosen as a model system since it is responsive to interferon (IFN) treatment and will enable mechanistic issues to be addressed. Under normal conditions, the blood-brain-barrier (BBB) limits the types of therapeutic approaches that can be used to treat not only glioma but also opportunistic infections in the brain. Prior studies in this laboratory have demonstrated that after single intravenous administration IFN is not detectable in normal mouse brain. However, It is detectable in the cerebral hemisphere ipsilateral to BBB disruption when administered following the osmotic alteration of the BBB with intracarotid administration of arabinose. Because of the controversy surrounding the clinical application of osmotic BBB alteration, alternative therapeutic approaches for cerebral glioma will also be evaluated. They will include slow and constant IFN delivery using an osmotic mini pump placed: 1) subcutaneously (sc), 2) intracerebrally (ic), or 3) intravenously (iv) in glioma bearing animals. The results of this approach will be compared to the results obtained after repeated systemic administration of IFN. A reproducible model of cerebrally implanted mouse glioma (G-26 in C57BL/6 mice) has been established in this laboratory. Biological and immunoenzymatic assays will be used to measure levels of IFNs in plasma and in the tumorous brain. IFN effects on tumor progression will be assessed by animal median survival times, glioma cell proliferation, brain macrophage infiltration, major histocompatibility (MHC) class 11 (la) antigen induction, and glioma glycosaminoglycan (GAG) coat synthesis. Brain levels of norepinephhne and plasma levels of ACTH and corticosterone will be assessed due to evidence of bidrectional influences between IFN and the hypothalamic-pituitary-adrenal axis. Although the proposed studies will evaluate more effective ways of treating brain tumors, the protocols may also have utility in treating AIDS related opportunistic infections of the brain. They will also provide a better understanding of how IFN might activate defense mechanisms within the normal and diseased brain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS028989-01
Application #
3415690
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1990-07-01
Project End
1993-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
1
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of South Florida
Department
Type
Schools of Medicine
DUNS #
City
Tampa
State
FL
Country
United States
Zip Code
33612
Wiranowska, M; Ransohoff, J; Weingart, J D et al. (1998) Interferon-containing controlled-release polymers for localized cerebral immunotherapy. J Interferon Cytokine Res 18:377-85
Naidu, K A; Wiranowska, M; Phuphanich, S et al. (1996) Modulation of glioma cell growth and 5-lipoxygenase expression by interferon. Anticancer Res 16:3475-82
Wiranowska, M; Prockop, L D; Naidu, A K et al. (1994) Interferon entry through the blood-brain barrier in glioma and its effect on lipoxygenase activity. Anticancer Res 14:1121-6
Wiranowska, M; Naidu, A K (1994) Interferon effect on glycosaminoglycans in mouse glioma in vitro. J Neurooncol 18:9-17
Naidu, A K; Wiranowska, M; Kori, S H et al. (1993) Inhibition of cell proliferation and glutathione S-transferase by ascorbyl esters and interferon in mouse glioma. J Neurooncol 16:1-10
Naidu, A K; Wiranowska, M; Kori, S H et al. (1993) Inhibition of human glioma cell proliferation and glutathione S-transferase by ascorbyl esters and interferon. Anticancer Res 13:1469-75
Wiranowska, M; Gonzalvo, A A; Saporta, S et al. (1992) Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model. J Neurooncol 14:225-36